APA (7th ed.) Citation

R, T., FJ, K., C, S., MJ, N., S, D., S, Z., . . . DG, P. (2023). Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell reports, 42(4), 112297. https://doi.org/10.1016/j.celrep.2023.112297

Chicago Style (17th ed.) Citation

R, Tiedt, et al. "Integrated CRISPR Screening and Drug Profiling Identifies Combination Opportunities for EGFR, ALK, and BRAF/MEK Inhibitors." Cell Reports 42, no. 4 (2023): 112297. https://doi.org/10.1016/j.celrep.2023.112297.

MLA (9th ed.) Citation

R, Tiedt, et al. "Integrated CRISPR Screening and Drug Profiling Identifies Combination Opportunities for EGFR, ALK, and BRAF/MEK Inhibitors." Cell Reports, vol. 42, no. 4, 2023, p. 112297, https://doi.org/10.1016/j.celrep.2023.112297.